Clinic Roundup

Trimel Pharmaceuticals Corp., of Toronto, said the FDA accepted its investigational new drug application for its bio-adhesive intranasal gel product development program, TBS-2. The company's TBS-2 product is being developed to treat the subset indication of the female sexual dysfunction anorgasmia. And IND was submitted in June.